Fraunhofer-Gesellschaft

Publica

Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.
2020Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis
Stürner, K.H.; Werz, O.; Koeberle, A.; Otto, M.; Pless, O.; Leypoldt, F.; Paul, F.; Heesen, C.
Zeitschriftenaufsatz
2018Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring
Stoessel, D.; Stellmann, J.-P.; Willing, A.; Behrens, B.; Rosenkranz, S.C.; Hodecker, S.C.; Stürner, K.H.; Reinhardt, S.; Fleischer, S.; Deuschle, C.; Maetzler, W.; Berg, D.; Heesen, C.; Walther, D.; Schauer, N.; Friese, M.A.; Pless, O.
Zeitschriftenaufsatz
2017A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial)
Stürner, K.H.; Stellmann, J.-P.; Dörr, J.; Paul, F.; Friede, T.; Schammler, S.; Reinhardt, S.; Gellissen, S.; Weissflog, G.; Faizy, T.D.; Werz, O.; Fleischer, S.; Vaas, L.A.I.; Herrmann, F.; Pless, O.; Martin, R.; Heesen, C.
Zeitschriftenaufsatz
2016Boswellic acids immunomodulate T cell populations in relapsing-remitting multiple sclerosis in the SABA phase IIa clinical trial
Stürner, K.H.; Stellmann, J.-P.; Dörr, J.-M.; Paul, F.; Keminer, O.; Vaas, L.; Pless, O.; Martin, R.; Heesen, C.
Abstract
2014A multiple sclerosis-associated variant of CBLB links genetic risk with type I IFN function
Stürner, K.H.; Borgmeyer, U.; Schulze, C.; Pless, O.; Martin, R.
Zeitschriftenaufsatz